Selective BRAF inhibitor Dabrafenib combined with a selective MAPK kinase (MEK) inhibitor trametinib successfully prolonged the progression-free survival of melanoma patients with BRAFV600E mutations in a phase I/II clinical trials (Flaherty et al., 2012). This evidence concerns the gene MAP2K7 and melanoma.